New Coronavirus Disease 2019 (COVID-19)
Conditions
Interventions
Structured evaluations to ascertain mental state, cognition and neurological signs
correlations with COVID-related clinical symptoms and biological markers. The assessment protocol will be applied to all participants (cases and controls). In brief, the interventions will comprise:
1
post-traumatic stress disorder ()PCL-C)
psychosis (SCID-5-RV)
alcohol use disorders (AUDIT) e suicide risk (ASQ).
2) Neurological examination: (a) Brief cognitive assessment: level of arousal and consciousness
temporal orientation
language. (b) Somatic examination: pronator drift test
speed of movement, upper limbs (finger tap, forearm rolling test)
extensor plantar skin reflex/Babinnski sign
cerebelar ataxia (index-nose test and gait)
sensitivity (only in patients with abnormal response in thermal/pain sensitivity test on four limbs). (c) cranial nerves: ocular and facial motricity
gaze-evoked nistagmus. (d) meningeal signs: nuchal rigidity, Brudzinski sign.
3) Neuropsichological examination: verbal IQ according to vocabulary and similarities (as an estimate of pre-morbid IQ). N
9615
54753
Sponsors
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP)
Laboratórios de Investigação Médica (LIMs) - HCFMUSP
Eligibility
Inclusion criteria
Inclusion criteria: Previous history of COVID-19 leading to significant medical morbidity/hospital admission and willingness/consent to perform follow-up interviews and examinations starting 6 months after remission of index episode/hospital discharge
Exclusion criteria
Exclusion criteria: Unavailability or refusal to perform multidisciplinary evaluations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome: incidence of psychiatric symptoms in the long-term outcome post-COVID19; method to ascertain outcome: psychiatric assessment protocol comprising the Clinical Interview Schedule - Revised (CIS-R), Structured Clinical Interview for DSM-5 Disorders, Revised (SCID-5-RV), Hospital Anxiety and Depression Scale (HADS), Post-Traumatic Stress Disorder Checklist (PCL-C), Ask Suicide-Screening Questions (ASQ), Alcohol Use Disorder Identification Test (AUDIT); criterion: classification of 'positive' and 'negative' cases according to the output of structured interviews (CIS-R and SCID_VR) and cut-off scores defined for the instruments. Secondary outcomes: incidence of memory complaints and neuropsychological symptoms in the long-term outcome post-COVID19; method to ascertain outcome: cognitive assessment battery comprising: Memory Complaint Scale (MCS), Mini-Mental State Examination (MMSE ), Memory Sub-scale of the Consortium to Establish a Diagnostic Registry for Alzheimer's Disease (CERAD), Trail-Making Test Version A (TMT-A), Verbal Fluency Test (VFT); criterion: classification of 'positive' and 'negative' cases according to cut-off scores defined for the instruments. | — |
Countries
Brazil
Contacts
Public ContactRodolfo Damiano
Outcome results
None listed